title: Effect of addition of hyaluronic acids on the osteoconductivity and biodegradability of synthetic octacalcium phosphate.
abstract: The present study was designed to investigate whether three sodium hyaluronic acid (HyA) medical products, Artz(®), Suvenyl(®) and a chemically modified derivative of sodium HyA Synvisc(®), can be used as suitable vehicles for an osteoconductive octacalcium phosphate (OCP). OCP granules (300-500 μm diameter) were mixed with these sodium HyAs with molecular weights of 90 × 10(4) (Artz(®)), 190 × 10(4) (Suvenyl(®)) and 600 × 10(4) (Synvisc(®)) (referred to as HyA90, HyA190 and HyA600, respectively). OCP-HyA composites were injected using a syringe into a polytetrafluoroethylene ring, placed on the subperiosteal region of mouse calvaria for 3 and 6 weeks, and then bone formation was assessed by histomorphometry. The capacity of the HyAs for osteoclast formation from RAW264 cells with RANKL was examined by TRAP staining in vitro. Bone formation was enhanced by the OCP composites with HyA90 and HyA600, compared to OCP alone, through enhanced osteoclastic resorption of OCP. HyA90 and HyA600 facilitated in vitro osteoclast formation. The results suggest that the osteoconductive property of OCP was accelerated by the HyAs-associated osteoclastic resorption of OCP, and therefore that HyA/OCP composites are attractive bone substitutes which are injectable and bioactive materials.
authors.affiliation: Department of Orthopaedic Surgery, Tohoku University School of Medicine, Sendai 980-8574, Japan; Division of Craniofacial Function Engineering, Tohoku University Graduate School of Dentistry, Sendai 980-8575, Japan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Suzuki
authors.forename: Takahisa
authors.initials: T
authors.lastname: Anada
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Naohisa
authors.initials: N
authors.lastname: Miyatake
authors.forename: Yoshitomo
authors.initials: Y
authors.lastname: Honda
authors.forename: Koshi N
authors.initials: KN
authors.lastname: Kishimoto
authors.forename: Masami
authors.initials: M
authors.lastname: Hosaka
authors.forename: Hideki
authors.initials: H
authors.lastname: Imaizumi
authors.forename: Eiji
authors.initials: E
authors.lastname: Itoi
authors.forename: Osamu
authors.initials: O
authors.lastname: Suzuki
mesh_terms: D000135:Acid Phosphatase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001861:Bone Regeneration / Q000187:drug effects*; D002130:Calcium Phosphates / Q000494:pharmacology*; D002460:Cell Line; D006801:Humans; D006820:Hyaluronic Acid / Q000494:pharmacology*; D020007:Implants, Experimental; D007527:Isoenzymes / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008970:Molecular Weight; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D015675:Osteocalcin / Q000378:metabolism; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D010012:Osteogenesis / Q000187:drug effects; D053245:RANK Ligand / Q000494:pharmacology; D012886:Skull / Q000187:drug effects; D017550:Spectroscopy, Fourier Transform Infrared; D000071681:Tartrate-Resistant Acid Phosphatase; D014783:Viscosity / Q000187:drug effects; D014961:X-Ray Diffraction
chemical_list: D002130:Calcium Phosphates; D007527:Isoenzymes; D053245:RANK Ligand; D015675:Osteocalcin; C022045:octacalcium phosphate; D006820:Hyaluronic Acid; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; C000605511:Acp5 protein, mouse; D000071681:Tartrate-Resistant Acid Phosphatase
keywords: Biodegradation; Bone regeneration; Hyaluronan products; Injectability; Octacalcium phosphate